Modulation by antenatal therapies of cardiovascular and renal programming in male and female offspring of preeclamptic rats
- 1 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 394 (11), 2273-2287
- https://doi.org/10.1007/s00210-021-02146-7
Abstract
Morbidity and mortality risks are enhanced in preeclamptic (PE) mothers and their offspring. Here, we asked if sexual dimorphism exists in (i) cardiovascular and renal damage evolved in offspring of PE mothers, and (ii) offspring responsiveness to antenatal therapies. PE was induced by administering NG-nitro-L-arginine methyl ester (L-NAME, 50 mg/kg/day, oral gavage) to pregnant rats for 7 days starting from gestational day 14. Three therapies were co-administered orally with L-NAME, atrasentan (endothelin ETA receptor antagonist), terutroban (thromboxane A2 receptor antagonist, TXA2), or α-methyldopa (α-MD, central sympatholytic drug). Cardiovascular and renal profiles were assessed in 3-month-old offspring. Compared with offspring of non-PE rats, PE offspring exhibited elevated systolic blood pressure and proteinuria and reduced heart rate and creatinine clearance (CrCl). Apart from a greater bradycardia in male offspring, similar PE effects were noted in male and female offspring. While terutroban, atrasentan, or α-MD partially and similarly blunted the PE-evoked changes in CrCl and proteinuria, terutroban was the only drug that virtually abolished PE hypertension. Rises in cardiorenal inflammatory (tumor necrosis factor alpha, TNFα) and oxidative (isoprostane) markers were mostly and equally eliminated by all therapies in the two sexes, except for a greater dampening action of atrasentan, compared with α-MD, on tissue TNFα in female offspring only. Histopathologically, antenatal terutroban or atrasentan was more effective than α-MD in rectifying cardiac structural damage, myofiber separation, and cytoplasmic alterations, in PE offspring. The repair by antenatal terutroban or atrasentan of cardiovascular and renal anomalies in PE offspring is mostly sex-independent and surpasses the protection offered by α-MD, the conventional PE therapy.Keywords
This publication has 84 references indexed in Scilit:
- Hypertensive Disorders of Pregnancy and Cardiometabolic Health in Adolescent OffspringHypertension, 2013
- Endothelin: Key Mediator of Hypertension in PreeclampsiaAmerican Journal of Hypertension, 2011
- Pulmonary and Systemic Vascular Dysfunction in Young Offspring of Mothers With PreeclampsiaJournal of the American College of Cardiology, 2010
- Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early AtherosclerosisHypertension, 2008
- Uterine Vascular Function in a Transgenic Preeclampsia Rat ModelHypertension, 2008
- Neutrophils from pregnant women produce thromboxane and tumor necrosis factor-α in response to linoleic acid and oxidative stressAmerican Journal of Obstetrics and Gynecology, 2005
- Role of Endothelin in Mediating Tumor Necrosis Factor-Induced Hypertension in Pregnant RatsHypertension, 2005
- Role of Endothelin-1 in Blood Pressure Regulation in a Rat Model of Visceral Obesity and HypertensionHypertension, 2004
- Gender Differences in ET and NOS Systems in ET B Receptor–Deficient RatsHypertension, 2003
- Selective Antagonism of the ETA Receptor, but Not the ETB Receptor, Is Protective Against Ischemic Acute Renal Failure in RatsThe Japanese Journal of Pharmacology, 2000